

# BASILEA PHARMACEU

ISIN: CH0011432447 WKN: 1143244 Asset Class: **Stock**

## Company



2024/09/27 10:10:53

Price

**47.00**

CHF

Difference

**-0.21% (-0.10)**



## Contact Details

BASILEA PHARMACEUTICA  
AG

Tel: +41-61-606-11-11

- -

Fax: +

Hegenheimermattweg 167b

Web:

4123 Allschwil

<http://www.basilea.com>

E-mail: [info@basilea.com](mailto:info@basilea.com)

## Company Profile

Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. Its products include antifungals and antibiotics. The company was founded on October 17, 2000, and is headquartered in Allschwil, Switzerland.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	152,145,000		175,364,000		241,066,000	
<b>Common stock capital</b>		13,100,000		13,093,000		12,992,000
<b>Fixed assets</b>	21,144,000		45,484,000		6,201,000	
<b>Equity capital of a company</b>		-10,003,000		-20,715,000		-58,607,000
<b>Cash and cash equivalents</b>	12,489,000		36,567,000		54,953,000	
<b>Accrued liabilities</b>		15,149,000		8,337,000		24,986,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		47,592,000		74,850,000		174,408,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		135,700,000		166,713,000		131,466,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		9,460,000		10,693,000		11,926,000
<b>Total assets</b>	173,289,000	173,289,000	220,848,000	220,848,000	247,267,000	247,267,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	US-GAAP	US-GAAP	US-GAAP
<b>Employees</b>	147	154	154
<b>Equity ratio</b>	-5.77%	-9.38%	-23.70%
<b>Debt-equity ratio</b>	-1,832.37%	-1,166.13%	-521.91%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	0.10%	-0.37%	-0.54%

# BASILEA PHARMACEU

ISIN: CH0011432447 WKN: 1143244 Asset Class: **Stock**

## Income statement

	2023	2022	2021
Turnover	157,634,000	147,765,000	148,122,000
Net income	10,451,000	12,147,000	-6,831,000
EBIT	25,695,234	24,067,629	4,439,209
Operating income before taxes	10,461,000	12,102,000	-6,794,000
Cash Flow	14,245,000	7,056,000	-32,020,000
Net interest income	-13,867,000	-10,685,000	-10,997,000
Research and development expenses	77,852,000	73,804,000	93,157,000
Income taxes	10,000	-45,000	37,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	1,132,606	1,013,438	1,015,886

## Board of Directors

Alf Gunnar Martin Nicklasson	Member of the administrative board
Carole Sable	Member of the administrative board
Nicole Onetto	Member of the administrative board
Thomas Werner	Member of the administrative board
Leonard Kruimer	Member of the administrative board
Domenico Scala	Chairman of the administrative board

## Members of Management Board

David Veitch	Chairman of Managing Board
Gerrit Hauck	Member of Executive Committee
Laurenz Kellenberger	Member of Executive Committee
Marc Engelhardt	Member of Executive Committee
Adesh Kaul	Member of Executive Committee